Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Conclusions: Zanubrutinib was shown to be highly active in patients with R/R MCL, as demonstrated by a high rate of CR documented by PET-based imaging. Zanubrutinib was generally well-tolerated, consistent with previous reports of zanubrutinib treatment in patients with various B-cell malignancies.DisclosuresSong: Peking University Cancer Hospital (Beijing Cancer Hospital): Employment. Zhou: Affiliated Cancer Hospital of Zhengzhou University: Employment; Health and Family Planning Commission of Henan Province: Patents & Royalties: Scientific and technological innovative talents "51282" Project leaders; Henan Cancer Hospital: Consultancy, Employment; Natural Science Foundation of China: Research Funding. Jin: College of Medicine, Zhejiang University: Employment; The National Natural Science Foundation of China: Research Funding. Guo: BeiGene (Shanghai) Co., LTD: Employment. Wang: BeiGene (Shanghai) Co., LTD: Employment. Hilger: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Huang: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Novotny: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Osman: BeiGene USA: Employment, Equity Ownership. Zhu: Beijing Cancer Hospital: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Song, Y., Zhou, K., Zou, D., Zhou, J., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., Lv, F., Feng, R., Gao, S., Zhou, D., Guo, H., Wang, A., Hilger, J., Huang, J., Novotny, W., Osman, M., Zhu, J. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom ' s Macroglobulinemia Source Type: research